6-methoxy-2,2-dimethyl-2,3-dihydrobenzofuran

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 6-methoxy-2,2-dimethyl-2,3-dihydrobenzofuran
• 英文别名: 6-Methoxy-2,2-dimethyl-2,3-dihydrobenzofuran；6-methoxy-2,2-dimethyl-3H-1-benzofuran
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: ABAMCAXTFZBYFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-methoxy-2,2-dimethyl-2,3-dihydrobenzofuran 在 四甲基乙二胺 、 仲丁基锂 、 硼酸三甲酯 作用下， 以 四氢呋喃 、 环己烷 为溶剂， 反应 1.5h， 以53%的产率得到6-methoxy-2,2-dimethyl-2,3-dihydrobenzofuran-7-ylboronic acid
  参考文献：
  名称：

  Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals

  摘要：

  本发明涉及式I的化合物，其中X、R、R1、R2、D、E1、E2、E3、E4、G1、G2、G3和G4具有权利要求中所指示的含义，这些化合物是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备式I化合物的方法，它们的用途以及包含它们的药物组合物。

  公开号：

  US20140296296A1
• 作为产物：
  描述：

  1-(4-甲氧基苯基)-2-甲基丙烷-2-醇 在 碘苯二乙酸 、 palladium diacetate 、 lithium carbonate 作用下， 以 六氟苯 为溶剂， 反应 36.0h， 以75%的产率得到6-methoxy-2,2-dimethyl-2,3-dihydrobenzofuran
  参考文献：
  名称：

  Pd(II)-Catalyzed Hydroxyl-Directed C−H Activation/C−O Cyclization: Expedient Construction of Dihydrobenzofurans

  摘要：

  A Pd(II)-catalyzed C-H activation/C-O cyclization reaction directed by a proximate hydroxyl group has been developed. This reaction provides a new method for constructing dihydrobenzofurans, including spirocyclic analogues, a process that is potentially applicable to natural product synthesis.

  DOI：

  10.1021/ja105366u

文献信息

• [EN] BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS D'ACIDE BIARYL-PROPIONIQUE ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2014154726A1

  公开（公告）日：2014-10-02

  The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式(I)的化合物，其中X、R、R1、R2、D、E1、E2、E3、E4、G1、G2、G3和G4在权利要求中所示，这些化合物是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备式I化合物的方法，它们的用途以及包含它们的药物组合物。
• Biaryl-propionic acid derivatives and their use as pharmaceuticals
  申请人：SANOFI

  公开号：US09150526B2

  公开（公告）日：2015-10-06

  The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中X、R、R1、R2、D、E1、E2、E3、E4、G1、G2、G3和G4具有所述要求中指示的含义，它们是有价值的药物活性化合物。它们是蛋白酶卡他普星A的抑制剂，可用于治疗动脉硬化、心力衰竭、肾脏疾病、肝病或炎症性疾病等疾病。本发明还涉及式I化合物的制备方法、其用途以及包含它们的药物组成物。
• High-Yielding Palladium-Catalyzed Intramolecular Alkane Arylation:  Reaction Development and Mechanistic Studies
  作者：Marc Lafrance、Serge I. Gorelsky、Keith Fagnou

  DOI：10.1021/ja076588s

  日期：2007.11.28

  Palladium-catalyzed alkane arylation reactions with aryl halides are described for the preparation of 2,2-dialkyl-dihydrobenzofuran substrates. These reactions occur in excellent yield and very high selectivity for the formation of one sole product arising from a reaction at nearby methyl groups. Mechanistic and computational studies point to the involvement of a concerted, inner-sphere palladation-deprotonation pathway that is enabled by the presence of three-center agostic interactions at the transition state. This mechanism accurately predicts the experimentally observed kinetic isotope effect as well as the site selectivity and should be useful in the design of new reactions and catalysts.
• BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：EP2978754A1

  公开（公告）日：2016-02-03
• US9150526B2
  申请人：——

  公开号：US9150526B2

  公开（公告）日：2015-10-06